Recent health news highlights controversial language restrictions within the FDA, legal actions against vape distributors in ...

Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth. Dr. Jay Bhattacharya, NIH nominee, will shed stock in Walmart and Nvidia.

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Crane asked about therapy dogs a day earlier "some of the meltdowns that were going on." Trump signs order imposing sanctions on International Criminal Court over investigations of Israel Drinking ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.